The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 26, 2019

Filed:

Nov. 07, 2016
Applicants:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Michael T. Rudd, Collegeville, PA (US);

Edward J. Brnardic, Lansdale, PA (US);

Yuntae Kim, Yongin-Si, KR;

Robert S. Meissner, Newton, MA (US);

Vanessa L. Rada, Hatfield, PA (US);

Shawn J. Stachel, Perkasie, PA (US);

Celina V. Zerbinatti, Hamburg, DE;

Inventors:

Michael T. Rudd, Collegeville, PA (US);

Edward J. Brnardic, Lansdale, PA (US);

Yuntae Kim, Yongin-Si, KR;

Robert S. Meissner, Newton, MA (US);

Vanessa L. Rada, Hatfield, PA (US);

Shawn J. Stachel, Perkasie, PA (US);

Celina V. Zerbinatti, Hamburg, DE;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 243/08 (2006.01); C07D 295/16 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01); C07D 413/14 (2006.01); C07D 417/14 (2006.01); C07D 471/08 (2006.01); C07D 487/08 (2006.01); C07D 513/04 (2006.01); A61P 25/18 (2006.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01); A61P 3/10 (2006.01);
U.S. Cl.
CPC ...
C07D 295/16 (2013.01); A61P 3/10 (2018.01); A61P 25/16 (2018.01); A61P 25/18 (2018.01); C07D 243/08 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01); C07D 471/08 (2013.01); C07D 487/08 (2013.01); C07D 513/04 (2013.01);
Abstract

In its many embodiments, the present invention provides substituted cyanopyridine containing compounds of the Formula (I): and acceptable salts thereof, wherein R, R, R, R, R, X, Y, Q, and the moiety are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.


Find Patent Forward Citations

Loading…